Advances in clinical chemistry. Volume 61 /
edited by Gregory S. Makowski.
- 1 online resource (241 pages).
- Advances in Clinical Chemistry .
- Advances in Clinical Chemistry. .
Chapter Four: The Expanding Role of Tandem Mass Spectrometry in Optimizing Diagnosis and Treatment of Thyroid Disease. Includes index.
Front Cover; Advances in Clinical Chemistry; Copyright; Contents; Contributors; Preface; Chapter One: BNP Molecular Forms and Processing by the Cardiac Serine Protease Corin; 1. Introduction; 2. BNP Molecular Forms: Implications for Biomarker and Therapeutic Use in Cardiovascular Disease; 2.1. Background; 2.2. BNP signal peptide; 2.3. NT-proBNP1-76 and BNP1-32; 2.4. Degradation products: BNP3-32, BNP5-32, and smaller peptides; 2.5. ProBNP1-108; 3. BNP Paradox in Heart Failure; 4. BNP Processing and Propeptide Convertases; 5. Cardiac Serine Protease, Corin; 5.1. Expression and function. 5.1.1. General information under physiologic conditions5.1.2. Animal models; 5.1.3. Human corin single-nucleotide polymorphism; 5.1.4. Human disease states and gender differences; 5.2. Other topics; 5.2.1. BNP processing in the circulation; 5.2.2. Role of glycosylation on BNP molecular forms and processing; 6. Clinical Implication and Future Directions; Acknowledgments; References; Chapter Two: Current Applications of Cardiac Troponin T for the Diagnosis of Myocardial Damage; 1. Introduction; 2. Biology and Function; 2.1. History; 2.2. Cardiac myofibrillar apparatus. 2.3. Troponin complex function2.4. Troponin isoforms; 2.5. Myocardial ischemia and necrosis; 3. Troponin Assays; 3.1. History; 3.2. Principle of test; 3.3. Cutoffs and sensitivity; 3.4. Preanalytic factors; 3.5. Assay standardization; 4. TnT Clinical Applications; 4.1. Myocardial necrosis; 4.1.1. AMI with ST-segment elevation; 4.1.2. Acute coronary syndromes without persistent STEMIs (unstable angina and non-ST-segment myocardial infarction); 4.1.3. Differential diagnosis of increased troponin; 4.1.4. Practical recommendations for use; 4.2. Pulmonary artery embolism. 4.3. Pulmonary artery hypertension4.4. Heart failure; 4.5. Cardiomyopathies; 4.5.1. Dilated cardiomyopathy; 4.5.2. Hypertrophic cardiomyopathy; 4.5.3. Other cardiomyopathies; 4.6. Arrhythmias; 4.7. Cardiotoxicity induced by anticancer therapy; 4.7.1. Diagnostic methods; 4.7.2. Cardiac troponins; 5. Biologic Variability; 6. Conclusion; Acknowledgments; References; Chapter Three: Markers in Nonalcoholic Steatohepatitis; 1. Introduction; 2. Epidemiology and Associated Conditions; 3. Pathogenesis and Histological Features; 4. Clinical and Diagnostic Approach; 5. Liver Function Tests. 6. Adipokines, Endocrine Mediators, and Signaling Networks in NASH7. Cytokines and Inflammation Biomarkers; 8. Oxidative Stress Markers; 9. Noninvasive Serum Biomarkers of Fibrosis; 9.1. Indirect markers of fibrosis; 9.2. Direct markers of fibrosis; 9.2.1. Markers associated with matrix deposition; 9.2.2. Markers associated with matrix degradation; 9.3. Cytokines and other markers associated with hepatic fibrosis; 9.4. Diagnostic panels to assess NASH; 10. Potential Genetic Modifiers and Novel Markers; 11. Conclusion; References.
Volume 61 in the internationally acclaimed Advances in Clinical Chemistry contains chapters submitted from leading experts from academia and clinical laboratory science. Authors are from a diverse field of clinical chemistry disciplines and diagnostics, ranging from basic biochemical exploration to cutting-edge microarray technology. Written by authors representing the diverse field of clinical chemistry and diagnostics, reviews in Advances in Clinical Chemistry cover a range of cutting-edge research ranging from basic biochemical exploration to microarray technolog.
9780124078277 (electronic bk.) 0124078273 (electronic bk.)
Clinical chemistry.
HEALTH & FITNESS / Diseases / General
MEDICAL / Clinical Medicine
MEDICAL / Diseases
MEDICAL / Evidence-Based Medicine
MEDICAL / Internal Medicine
Electronic books.
RB40 / .A383 2013eb
616.0756
Chapter Four: The Expanding Role of Tandem Mass Spectrometry in Optimizing Diagnosis and Treatment of Thyroid Disease. Includes index.
Front Cover; Advances in Clinical Chemistry; Copyright; Contents; Contributors; Preface; Chapter One: BNP Molecular Forms and Processing by the Cardiac Serine Protease Corin; 1. Introduction; 2. BNP Molecular Forms: Implications for Biomarker and Therapeutic Use in Cardiovascular Disease; 2.1. Background; 2.2. BNP signal peptide; 2.3. NT-proBNP1-76 and BNP1-32; 2.4. Degradation products: BNP3-32, BNP5-32, and smaller peptides; 2.5. ProBNP1-108; 3. BNP Paradox in Heart Failure; 4. BNP Processing and Propeptide Convertases; 5. Cardiac Serine Protease, Corin; 5.1. Expression and function. 5.1.1. General information under physiologic conditions5.1.2. Animal models; 5.1.3. Human corin single-nucleotide polymorphism; 5.1.4. Human disease states and gender differences; 5.2. Other topics; 5.2.1. BNP processing in the circulation; 5.2.2. Role of glycosylation on BNP molecular forms and processing; 6. Clinical Implication and Future Directions; Acknowledgments; References; Chapter Two: Current Applications of Cardiac Troponin T for the Diagnosis of Myocardial Damage; 1. Introduction; 2. Biology and Function; 2.1. History; 2.2. Cardiac myofibrillar apparatus. 2.3. Troponin complex function2.4. Troponin isoforms; 2.5. Myocardial ischemia and necrosis; 3. Troponin Assays; 3.1. History; 3.2. Principle of test; 3.3. Cutoffs and sensitivity; 3.4. Preanalytic factors; 3.5. Assay standardization; 4. TnT Clinical Applications; 4.1. Myocardial necrosis; 4.1.1. AMI with ST-segment elevation; 4.1.2. Acute coronary syndromes without persistent STEMIs (unstable angina and non-ST-segment myocardial infarction); 4.1.3. Differential diagnosis of increased troponin; 4.1.4. Practical recommendations for use; 4.2. Pulmonary artery embolism. 4.3. Pulmonary artery hypertension4.4. Heart failure; 4.5. Cardiomyopathies; 4.5.1. Dilated cardiomyopathy; 4.5.2. Hypertrophic cardiomyopathy; 4.5.3. Other cardiomyopathies; 4.6. Arrhythmias; 4.7. Cardiotoxicity induced by anticancer therapy; 4.7.1. Diagnostic methods; 4.7.2. Cardiac troponins; 5. Biologic Variability; 6. Conclusion; Acknowledgments; References; Chapter Three: Markers in Nonalcoholic Steatohepatitis; 1. Introduction; 2. Epidemiology and Associated Conditions; 3. Pathogenesis and Histological Features; 4. Clinical and Diagnostic Approach; 5. Liver Function Tests. 6. Adipokines, Endocrine Mediators, and Signaling Networks in NASH7. Cytokines and Inflammation Biomarkers; 8. Oxidative Stress Markers; 9. Noninvasive Serum Biomarkers of Fibrosis; 9.1. Indirect markers of fibrosis; 9.2. Direct markers of fibrosis; 9.2.1. Markers associated with matrix deposition; 9.2.2. Markers associated with matrix degradation; 9.3. Cytokines and other markers associated with hepatic fibrosis; 9.4. Diagnostic panels to assess NASH; 10. Potential Genetic Modifiers and Novel Markers; 11. Conclusion; References.
Volume 61 in the internationally acclaimed Advances in Clinical Chemistry contains chapters submitted from leading experts from academia and clinical laboratory science. Authors are from a diverse field of clinical chemistry disciplines and diagnostics, ranging from basic biochemical exploration to cutting-edge microarray technology. Written by authors representing the diverse field of clinical chemistry and diagnostics, reviews in Advances in Clinical Chemistry cover a range of cutting-edge research ranging from basic biochemical exploration to microarray technolog.
9780124078277 (electronic bk.) 0124078273 (electronic bk.)
Clinical chemistry.
HEALTH & FITNESS / Diseases / General
MEDICAL / Clinical Medicine
MEDICAL / Diseases
MEDICAL / Evidence-Based Medicine
MEDICAL / Internal Medicine
Electronic books.
RB40 / .A383 2013eb
616.0756